TRB Chemedica International SA is a market-leading pharmaceutical and biotechnology company with global operations, headquartered in Switzerland. The company has successfully developed, produced, and promoted APIs, pharmaceutical products, and medical devices in the fields of ophthalmology, rheumatology, and neurology for more than 30 years.
TRB Chemedica International SA was founded in 1980 by Dr. Guido Di Napoli and has since grown through the establishment of a global network of subsidiaries and distributors. With over 30 years of expertise, the company has been one of the pioneers in the creation of medical devices based on biofermentation-derived hyaluronic acid for intra-articular application and the treatment of dry eye. All TRB Chemedica International products meet the highest global standards and ensure patient satisfaction and safety. TRB Chemedica is headquartered in Geneva, Switzerland and is present in more than 70 countries.
Through the development of Ostenil, a hyaluronic acid formulation for intra-articular usage, TRB Chemedica has set new benchmarks in the treatment of osteoarthritis. Launched in 1998, Ostenil has proven to be highly successful in reducing pain and improving mobility in patients with degenerative and traumatic diseases of synovial joints, such as osteoarthritis. The Ostenil range consists of four products: Ostenil, Ostenil Tendon, Ostenil Plus, and Ostenil Mini, which are all suitable for any synovial joint — from head to toe. Ostenil treatments are safe and well-tolerated, lasting up to 12 months.
TRB Chemedica also offers Viscoseal, which has been specially designed to replace the synovial fluid after an arthroscopy and therefore to prevent post-operative complications. The solution temporarily substitutes the body’s own synovial fluid thanks to the lubricating and shock-absorbing properties of hyaluronic acid.
As part of its mission to enhance patients’ quality of life, TRB Chemedica Products produces high-quality pharmaceutical products that are known for their optimum performance, safety, and longevity. The development of cutting-edge products has been made possible thanks to high-level international scientific collaboration programs (e.g., with the Faculty of Pharmacy at the University of Geneva, and other universities throughout the world). The superiority of TRB’s medical devices is ensured by the use of only top-of-the-line components and innovative manufacturing technologies.
